First-Line Data From AMIGO-1 and COPERNICUS, EGFR Result in Central Nervous System Involvement, and KRAS G12C in Practice

The faculty discuss 2 first-line reports from the 2026 World Conference on Lung Cancer. For AMIGO-1, a single-arm phase 2 study adding pemetrexed to amivantamab and lazertinib, they weigh the efficacy signal against treatment-related deaths and the limits of a single-arm study with a historical benchmark. For COPERNICUS, they discuss subcutaneous amivantamab with lazertinib, prophylactic anticoagulation, and enhanced dermatologic prophylaxis, and the results presented at WCLC. The faculty then discuss how far the EGFR result carries in patients with central nervous system involvement, including the report in leptomeningeal disease after high-dose tyrosine kinase inhibitor therapy, and turn to where KRAS G12C sits in practice today.